Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
109 participants
INTERVENTIONAL
2003-01-31
2007-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Bexarotene With Narrow-Band UVB for Psoriasis
NCT00151008
Narrowband UVB Light Therapy to Patients With Dark Skin Types Who Have 10% of Their Body Involved With Psoriasis Vulgaris.
NCT00220025
Apremilast 30mg Bid With Narrowband UVB in the Treatment of Plaque Psoriasis
NCT02412644
Safety and Efficacy of Combining nbUVB to Etanercept in Patients
NCT00640393
Utilization of Narrow Band Ultraviolet B (UVB) Light Therapy and Etanercept for the Treatment of Psoriasis
NCT00110981
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
group 1
Erythematogenic irradiation scheme
UVB phototherapy
Group 1: every irradiation an increase of 40%, starting with 70% of the minimal erythema dose
group 2
Suberythematogenic irradiation scheme
UVB phototherapy
Group 2: every irradiation an increase of 20%, starting with 30% of the minimal erythema dose
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
UVB phototherapy
Group 1: every irradiation an increase of 40%, starting with 70% of the minimal erythema dose
UVB phototherapy
Group 2: every irradiation an increase of 20%, starting with 30% of the minimal erythema dose
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Older than 18 years
Exclusion Criteria
* No systemic medication for 4 weeks
* No medication (betablocker, lithium) interfering with psoriasis
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Radboud University Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Radboud University Nijmegen Medical Centre
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Rianne Gerritsen, MD, PhD
Role: STUDY_DIRECTOR
Radboud University Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Radboud University Nijmegen Medical Centre, Department of Dermatology
Nijmegen, Nijmegen, Netherlands
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UVB-MKL
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.